Previous 10 | Next 10 |
ALACHUA, Fla. and TAMPA, Fla., July 19, 2021 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or discontinuity to peripheral nerves, today announced that John H. Johnson has been appointed to its Board of D...
Transaction Preserves $31.2 Million in Cash Cash Runway Expected Until at Least 2024 to Deliver on Current Programs Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients battling cancer, today announced that i...
Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This report optimizes tradi...
Baker Brothers’ 13F portfolio value decreased from $26.54B to $23.07B this quarter. The large stake in Alexion Pharmaceuticals was decreased during the quarter. The top three positions are Seagen, BeiGene, and Incyte Corporation and they add up to almost ~57% of the portfol...
Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This report optimizes tradi...
Verastem Inc. (NASDAQ:VSTM) traded at a new 52-week high today of $4.14. This new high was reached on below average trading volume as 2.1 million shares traded hands, while the average 30-day volume is approximately 3.3 million shares. Verastem Inc. share prices have moved between a 52-w...
Shares of Verastem Inc. (NASDAQ:VSTM) traded today at $4.17, eclipsing its 52-week high. Approximately 2.1 million shares have changed hands today, as compared to an average 30-day volume of 3.3 million shares. There is potential upside of 110.7% for shares of Verastem Inc. based on a cu...
Verastem Oncology (Nasdaq:VSTM), a biopharmaceutical company committed to developing and commercializing new medicines for patients battling cancer, today announced the appointments of Paul Bunn, M.D., and Lesley Solomon to its Board of Directors, adding additional strength in the areas...
Verastem has been up a lot recently. Its RAF/MEK dual inhibitor VS-6766 has shown promise. There are no major near-term catalysts. For further details see: Verastem: Catalyst Desert Looms
Dogecoin (CRYPTO: DOGE) , in many ways, is at the epicenter of the cryptocurrency craze. Its price appreciated by a staggering 12,000% during just the first five months of 2021. The probability that this star of the cryptocurrency world will keep churning higher, however, appears to...
News, Short Squeeze, Breakout and More Instantly...
A look at the top 10 most actives in the United States Sangamo Therapeutics Inc. (SGMO) rose 50.7% to $0.604699 on volume of 90,844,210 shares Selina Hospitality PLC (SLNA) rose 7.7% to $0.028 on volume of 57,431,570 shares NuZee Inc. (NUZE) rose 260.1% to $3.7094 on volume of 53,639,595 ...
Verastem Oncology, (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced the pricing of an underwritten public offering of 13,333,334 shares of its common stock and accompanying warrants to purchase up to 13,333,334 shares of it...
Verastem Oncology, (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced that it intends to offer and sell shares of its common stock and accompanying warrants to purchase shares of common stock, as well as pre-funded warrants t...